The Study of Equity Financing Efficiency in Pharmaceutical Enterprises under the Constraint of Bad Debt---Empirical Analysis based on 155 Listed Enterprises

LIUJin-shan,MAIJian-ming
DOI: https://doi.org/10.14007/j.cnki.cjpl.2015.06.014
2015-01-01
Abstract:This paper applies SBM directional distance function to measure the equity financing efficiency of public pharmaceutical enterprises in China under the constraint of bad debt,and analyzes the influence of macroeconomic factors and differences among Multi-level capital markets. The equity financing efficiency of public pharmaceutical enterprises on SME and GEM is better than that on the Main Board. Intangible asset growth rate is the main source of equity financing inefficiency. The development in China’s capital market and the degree of aging affect equity financing efficiency signally.
What problem does this paper attempt to address?